نتائج البحث

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1413/1223Test; Bubendor F.L., Schopfer A., Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-83. DOI:10.1053/hp.2000.6698.; Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270-3. DOI:10.1016/j.eururo.2013.10.055.; Mottet N., Cornford P., van der Bergh R.C.N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer (2020). Available at: https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020v4.pdfTest.; Schaeffer E., Srinivas S., Antonarakis E. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) -prostate cancer (version 3.2020) (2020). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfTest.; Клинические рекомендации Ассоциации онкологов России по лечению пациентов с раком предстательной железы 2020. Доступно по: https://oncology-association.ru/wp-content/uploads/2020/09/rak_predstatelnoj_zhelezy.pdfTest.; Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. DOI:10.1056/NEJMoa1213755.; Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, doubleblind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397-406. DOI:10.1016/S1470-2045(14)70474-7.; Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castrationresistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306-16. DOI:10.1016/S1470-2045(16)30173-5.; Higano C.S., Saad F., Sartor A.O. et al. Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020;38(6_suppl):32. DOI:10.1200/JCO.2020.38.6_suppl.32.; Клинические рекомендации «Рак предстательной железы» Минздрава России 2020. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/99Test.; Higano C.S., Harshman L.C., Dizdarevic S. et al. Safety and overall survival (OS) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. J Clin Oncol 2020;38 (15_suppl):5542.; Dizdarevic S., Petersen M.D., Essler M. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in nonintervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imag 2019;46:1102-10. DOI:10.1007/s00259-019-4261-y.; Smith M., Parker C., Saad F. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. DOI:10.1016/S1470-2045(18)30860-X.; European Medicines Agency (EMA). EMA restricts use of prostate cancer medicine Xofigo. 2018. Available at: https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigoTest.; Shore N.D., Tutrone R.F., Mariados N.F. et al. eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16(2):149-54. DOI:10.1016/j.clgc.2017.10.022.; Shore N., Higano C.S., George D.J. et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2020;23:680-8. DOI:10.1038/s41391-020-0236-0.; Poeppel T., Eschmann S., Werner A. et al. 828 P Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): an interim review of a prospective, noninterventional study (PARABO). Annal Oncol 2020;29(Suppl 8):VIII289-90. DOI:10.1093/annonc/mdy284.037.; Sternberg C.N., Saad F., Graff J.N. et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol 2020;31(2):257-65. DOI:10.1016/j.annonc.2019.10.025.; Sartor O., Vogelzang N.J., Sweeney C. et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist 2018;23(2):193-202. DOI:10.1634/theoncologist.2017-0413.; https://clinicaltrials.gov/ct2/show/NCT02194842Test.; https://clinicaltrials.gov/ct2/show/NCT03574571Test.; https://oncourology.abvpress.ru/oncur/article/view/1413Test

View record in BASE

5

دورية أكاديمية

Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists ; Применение аналогов лютеинизирующего гормона рилизинг-гормона у больных раком предстательной железы в рутинной клинической практике российских онкоурологов

المؤلفون: V. Matveev B., B. Alekseev Ya., B. Kamolov Sh., A. Markova S., В. Матвеев Б., Б. Алексеев Я., Б. Камолов Ш., А. Маркова С.

المصدر: Cancer Urology; Том 17, № 2 (2021); 83-92 ; Онкоурология; Том 17, № 2 (2021); 83-92 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: prostate cancer, androgen deprivation therapy, hormone therapy, luteinizing hormone-releasing hormone agonists, routine clinical practice, non-interventional study, рак предстательной железы, андроген-депривационная терапия, гормональная терапия, агонист лютеинизирующего гормона рилизинг-гормона, рутинная клиническая практика, неинтервенционное исследование

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1466/1276Test; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старин-ского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.; Mottet N., Cornford P., van den Bergh R.C.N. et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology, 2021. P. 212.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. DOI:10.7326/0003-4819-132-7200004040-00009; Rick F.G., Schally A.V. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol Oncol 2015;33(6):270-4. DOI:10.1016/j.urolonc.2014.11.006.; Schally A.V., Block N.L., Rick F.G. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate 2017;77(9):1036-54. DOI:10.1002/pros.23360.; Liu S.V., Liu S., Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs 2011;20(6):769-78. DOI:10.1517/13543784.2011.574611.; Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447-57. DOI:10.1517/14656566.5.2.447.; Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199-203. DOI:10.1097/01.ju.0000023895.95963.1b.; Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castratelevels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021-4. DOI:10.1016/s0090-4295(00)00793-7.; Матвеев В.Б., Маркова А.С. Финальные результаты проспективной многоцентровой наблюдательной программы RU-EGD-NI-001 по оценке эффективности и переносимости 6-месячной депо-формы Элигарда 45 мг у больных распространенным раком предстательной железы в рутинной клинической практике российских онкоурологов. Онкоурология 2017;13(2):79-86. DOI:10.17650/1726-9776-2017-13-2-79-86.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. DOI:10.1186/1471-2490-11-15.; Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol 2015;67(1):177-9. DOI:10.1016/j.eururo.2014.08.055.; Рак предстательной железы. Клинические рекомендации. Ассоциация онкологов России, 2020.; Рак предстательной железы. Клинические рекомендации. Министерство здравоохранения Российской Федерации, 2021.; Klotz L., O'Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151-6. DOI:10.1200/JCO.2014.58.2973.; https://oncourology.abvpress.ru/oncur/article/view/1466Test